SynthesisCurrent cardiology reviews2026
Cancer-associated Marantic Endocarditis and Direct Oral Anticoagulants: Case Report and Systematic Review.
Synthesis in Current cardiology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNonbacterial thrombotic endocarditis (NBTE) involves sterile vegetations on heart valves due to systemic hypercoagulability, often linked to malignancies. It is frequently underdiagnosed and presents significant clinical management challenges, often manifesting as thromboembolic events like ischemic stroke. We aim to report the first case of cancerassociated NBTE that showed a positive response to rivaroxaban as a maintenance anticoagulant, with 3D echocardiographic evidence of vegetation reduction, and to evaluate the performance of direct oral anticoagulants (DOACs) in treating cancer-associated NBTE through a systematic review of case reports.
methodsA case study and a systematic review of case reports on the use of DOACs in the setting of cancer-associated non-valvular atrial fibrillation were presented. Electronic databases were searched, and relevant studies were selected based on predefined eligibility criteria. Data were extracted and analyzed qualitatively, focusing on demographics, clinical presentation, anticoagulation and anticancer therapies, and outcomes (surgery, NBTE resolution, thromboembolic events, and mortality). RESULTS AND DISCUSSION: In addition to our case, thirty-three studies were included in the systematic review. Most patients were already on DOAC therapy before the NBTE diagnosis. Lung and pancreatic cancers were the most common primary neoplasms. The aortic and mitral valves were most frequently affected. Anticoagulation therapy often shifted from DOACs to heparin upon NBTE diagnosis, with low-molecular-weight heparin showing better outcomes in vegetation resolution and thromboembolic event prevention. DISCUSSION: This study reinforces the suggestion that heparins are more appropriate for treating cancer-associated NBTE. However, satisfactory DOAC outcomes warrant further research.
conclusionEffective NBTE management with DOACs appears to be strongly associated with the successful control of the underlying neoplasm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.